LEADER 01052nam0-22003731i-450- 001 990001496880403321 005 20090804094208.0 010 $a1-55860-523-1 035 $a000149688 035 $aFED01000149688 035 $a(Aleph)000149688FED01 035 $a000149688 100 $a20021015d1998----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $aa---a---001yy 200 1 $aReadings in database systems$fMichael Stonebraker, Joseph M. Hellerstein (eds.) 205 $a3rd ed. 210 $aSan Francisco [Ca.]$cMorgan Kaufmann$dc1998 215 $axv, 685 p.$cill.$d28 cm 610 0 $aArchivi di dati 610 0 $aBasi di dati 610 0 $aDatabase management 676 $a005.74$v21 702 1$aHellerstein,$bJoseph M. 702 1$aStonebraker,$bMichael 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001496880403321 952 $a005.74-DAT-1$b1691$fSC1 952 $a005.74-DAT-1A$b1692$fSC1 959 $aSC1 996 $aReadings in database systems$9377506 997 $aUNINA LEADER 01030cam0-2200325---450- 001 990005480220403321 005 20101102155930.0 035 $a000548022 035 $aFED01000548022 035 $a(Aleph)000548022FED01 035 $a000548022 100 $a19990604e19651884km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $aArtisti veneti in Roma nei secoli 15., 16. e 17.$estudi e ricerche negli archivi romani$fper A. Bertolotti 210 $aBologna$cArnaldo Forni$dstampa 1965 215 $a99 p.$d25 cm 300 $aRistampa anastatica dell'ed. di Venezia, 1884 300 $aEd. di 200 esempl. 610 0 $aArtisti$aVeneto$aStoria$aSec. 15.-17. 676 $a709.453 700 1$aBertolotti,$bAntonino$f<1836-1893>$0212007 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990005480220403321 952 $a709.453 BER 1$bST. ARTE 7942$fFLFBC 959 $aFLFBC 996 $aArtisti veneti in Roma nei secoli 15., 16. e 17$9587433 997 $aUNINA LEADER 04019nam 2201045z- 450 001 9910595079403321 005 20220916 035 $a(CKB)5680000000080731 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92076 035 $a(oapen)doab92076 035 $a(EXLCZ)995680000000080731 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aEnhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes 210 $aBasel$d2022 215 $a1 online resource (204 p.) 311 08$a3-0365-4996-X 311 08$a3-0365-4995-1 330 $aThe regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have made these cells the focus of multiple pre-clinical studies and clinical trials. While the results from these clinical studies have established that MSCs are safe, the efficacy of these cells is not as well-established. In this regard, there have been increased efforts towards generating potentiated/activated MSCs with enhanced therapeutic efficacy. Research on the mechanisms for enhancing MSC potency and efficacy is an area of active study with great potential for translation into clinical settings. The purpose of this book is to bring together recent research from a broad range of topics relating to potentiation strategies for enhancing MSC therapeutic efficacy, including growth factor pre-conditioning, hypoxia, and 3D culture. The research compiled in this book increases the basic understanding of MSC culture techniques and describes some MSC preparations for potential novel therapeutic applications. 517 $aEnhancing Mesenchymal Stem Cells 606 $aMedicine and Nursing$2bicssc 610 $a3-methyladenine 610 $a3D culture 610 $aadipose tissue-derived stem cells (ASCs) 610 $aadipose-derived stem cell 610 $aAKB-6548 610 $aangiogenesis 610 $aastrocytes 610 $aautophagy 610 $aaxon growth 610 $aCD206 610 $acell therapy 610 $achemotaxis 610 $acombination therapy 610 $aengineered cardiac patches 610 $aexosome 610 $afibroblast growth factor 2 610 $ahepatocyte growth factor 610 $ahypoxia 610 $aIFN-? 610 $aimmunomodulation 610 $aimmunosuppression 610 $aiMSC secretome 610 $ainflammation 610 $aiPSC-derived MSCs 610 $aliver cirrhosis 610 $amacrophages 610 $amalignant pleural mesothelioma (MPM) 610 $amesenchymal stem cells 610 $amesenchymal stromal cells 610 $amesothelioma 610 $ananofiber-hydrogel composite 610 $aneural 610 $aneuroprotection 610 $aneurospheres 610 $aosteogenic differentiation 610 $aoxygen conditions 610 $aparacrine potential 610 $aphagocytosis 610 $aplacenta-derived mesenchymal stem cells 610 $apluripotency 610 $apolyunsaturated fatty acid 610 $apotentiation of iMSC efficacy 610 $apre-conditioning 610 $apreconditioning 610 $apriming 610 $aquiescence 610 $arapamycin 610 $asecondary injury 610 $asecretome 610 $asecretory profile 610 $aspheroids 610 $aspinal cord injury 610 $aumbilical cord 610 $aVadadustat 610 $aWharton's jelly mesenchymal stem cells 610 $aWKYMVm 615 7$aMedicine and Nursing 700 $aYlostalo$b Joni H$4edt$01289237 702 $aDurand$b Nisha C$4edt 702 $aYlostalo$b Joni H$4oth 702 $aDurand$b Nisha C$4oth 906 $aBOOK 912 $a9910595079403321 996 $aEnhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes$93030230 997 $aUNINA